325. Hereditary autoinflammatory syndrome Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 5 / Drugs : 11 - (DrugBank : 6) / Drug target genes : 2 - Drug target pathways : 35
Hereditary autoinflammatory syndrome and other diseases between which drug repositioning (DR) might occur (Sakate and Kimura 2021) . Circle size: Number of drugs, Line breadth: Score (Drug repositionability)
ID | Diseases (Sorted by score) | Score |
---|---|---|
325 | Hereditary autoinflammatory syndrome | - |
46 | Malignant rheumatoid arthritis | 2.000 |
49 | Systemic lupus erythematosus | 2.000 |
51 | Scleroderma | 2.000 |
65 | Primary immunodeficiency | 2.000 |
84 | Sarcoidosis | 2.000 |
96 | Crohn disease | 2.000 |
256 | Muscle glycogenosis | 2.000 |
53 | Sjogren syndrome | 2.000 |
271 | Ankylosing spondylitis | 2.000 |
162 | Pemphigoid | 2.000 |
228 | Bronchiolitis obliterans | 2.000 |
265 | Lipodystrophy | 2.000 |
93 | Primary biliary cholangitis | 2.000 |
50 | Dermatomyositis | 2.000 |
107 | Juvenile idiopathic arthritis | 2.000 |
97 | Ulcerative colitis | 2.000 |
40 | Takayasu arteritis | 2.000 |
41 | Giant cell arteritis | 2.000 |
269 | Pyogenic arthritis | 2.000 |
11 | Myasthenia gravis | 2.000 |
44 | Wegener granulomatosis | 2.000 |
268 | Nakajo-Nishimura syndrome | 2.000 |